relatlimab
Showing 1 - 25 of 25
Melanoma (Skin) Trial in Houston (BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab)
Not yet recruiting
- Melanoma (Skin)
- BMS-986213 (Relatlimab-Nivolumab FDC)
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 1, 2023
Metastatic Uveal Melanoma Trial in Miami (Nivolumab, Relatlimab)
Recruiting
- Metastatic Uveal Melanoma
- Nivolumab
- Relatlimab
-
Miami, FloridaUniversity of Miami Sylvester Comprehensive Cancer Center
Aug 23, 2022
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas
- Colorectal Adenocarcinoma
- Nivolumab
- Relatlimab
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
- MSI-H Tumors
- Nivolumab
- Relatlimab
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Basal Cell Carcinoma Trial in Baltimore (Nivolumab, Ipilimumab, Relatlimab)
Recruiting
- Basal Cell Carcinoma
- Nivolumab
- +2 more
-
Baltimore, MarylandJohns Hopkins Hospital
Mar 10, 2022
Hepatocellular Carcinoma Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Hepatocellular Carcinoma
- Nivolumab
- Relatlimab
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 3, 2022
Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Nivolumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 31, 2022
Nasopharyngeal Carcinoma Trial (procedure, drug, biological)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Biospecimen Collection
- +9 more
- (no location specified)
Sep 12, 2023
Cancer Trial in Hackensack (relatlimab, nivolumab, rHuPH20)
Active, not recruiting
- Cancer
- relatlimab
- +2 more
-
Hackensack, New JerseyHackensack University Medical Center
Sep 13, 2021
Carcinomas, Renal Medullary Carcinoma Trial in Houston (Nivolumab, Relatlimab)
Not yet recruiting
- Carcinomas
- Renal Medullary Carcinoma
- Nivolumab
- Relatlimab
-
Houston, TexasMD Anderson Cancer Center
Apr 20, 2022
Acute Myeloid Leukemia Trial in Munich (Azacitidine Injection, Nivolumab, Relatlimab)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine Injection
- +2 more
-
Munich, GermanyUniversity Hospital, LMU Munich
May 30, 2021
Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression Trial in Nashville (Nivolumab,
Terminated
- Metastatic Melanoma
- +2 more
- Nivolumab
- +2 more
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
Mar 26, 2021
Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer Trial in Herlev (Ipilimumab, Cyclophosphamid,
Recruiting
- Metastatic Ovarian Cancer
- +2 more
- Ipilimumab
- +5 more
-
Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK)
May 7, 2021
Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)
Recruiting
- Advanced Cancer
- Relatlimab
- +3 more
-
Duarte, California
- +23 more
Oct 24, 2022
Lymphoma, Non-Hodgkin, Hodgkin Disease Trial in Worldwide (Relatlimab, Nivolumab)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- Hodgkin Disease
- Relatlimab
- Nivolumab
-
Phoenix, Arizona
- +53 more
Aug 17, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
- Relatlimab
- +3 more
-
Los Angeles, California
- +62 more
Feb 1, 2023
Cancer Trial in Kashiwa-shi (Relatlimab, Nivolumab)
Active, not recruiting
- Cancer
- Relatlimab
- Nivolumab
-
Kashiwa-shi, Chiba, JapanLocal Institution
Dec 3, 2021
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in United States (JCAR017, Durvalumab,
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- JCAR017
- +7 more
-
Duarte, California
- +17 more
Jan 13, 2023
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction Trial in Essen (Nivolumab, relatlimab, Oxaliplatin)
Recruiting
- Gastric Cancer
- Adenocarcinoma of the Esophagogastric Junction
- Nivolumab
- +5 more
-
Essen, GermanyUniversity Hospital Essen
May 18, 2021
NSCLC, Recurrent NSCLC, Metastatic NSCLC Trial in Worldwide (Nivolumab, Relatlimab, Carboplatin)
Recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nivolumab
- +6 more
-
Arcadia, California
- +149 more
Oct 7, 2022
Advanced Gastric Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Relatlimab)
Active, not recruiting
- Advanced Gastric Cancer
- Nivolumab
- +4 more
-
Phoenix, Arizona
- +34 more
Aug 18, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022